Haemonetics Corporation   Report issue

For profit Phase 1 Phase 3 Phase 4
Founded: Braintree MA United States (1971)
Status: No NME R&D (1971)

Organization Overview

First Clinical Trial
2004
NCT00998088
First Marketed Drug
2004
sodium chloride
First NDA Approval
None
Last Known Activity
2012

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Alternative names

HAEMONETICS

Active Ingredients

Marketed Drugs (1)

sodium chloride (2004)

Drugs in Phase 4 Trials (7)

acetylsalicylic acid (aspirin) (2 trials)

clopidogrel (plavix) (2 trials)

epoetin (Epogen) (1 trial)

esomeprazole (nexium) (1 trial)

fondaparinux sodium (arixtra) (1 trial)

pantoprazole (protonix) (1 trial)

rabeprazole (pariet) (1 trial)

Drugs in Phase 3 Trials (2)

fibrinogen (human) (RiaSTAP) (1 trial)

sodium chloride (1 trial)

Drugs in Phase 1 Trials (1)

Key: Haemonetics Corporation (0) Acquired (1)

ivermectin (stromectol) (1 trial)

Drugs in Other Trials (1)

cilostazol (pletal) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Hemorrhage (Phase 3)

Osteoarthritis (Phase 4)

Postpartum Hemorrhage (Phase 3)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 6
  • # of Trial APIs: 11